U.S.FDAApprovesExpandedIndicationforVONVENDI[vonWillebrandfactor(Recombinant)]forAdultsandChildrenwithVonWillebrandDisease
===2025/9/8 13:05:41===
tements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States and with respect to international trade relations; competitive pressures and developments; changes to applicable laws and regulations, including tax, tariff and other trade-related rules; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus
=*=*=*=*=*=
当前为第14/17页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页